# GLP-1s and Worsening Mental Illness

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/glp1s-and-worsening-mental-illness

> Semaglutide was associated with 42% lower risk of worsening mental illness in people with depression and anxiety. Exenatide and dulaglutide showed nothing. Four drugs, one class, two very different results.

## Key points

- Semaglutide 0.58, liraglutide 0.82, exenatide 1.01, dulaglutide 1.01.
- Class-wide self-harm hazard ratio 0.56, in a population selected for depression and anxiety.
- Each person was compared with themselves, which removes stable differences between people but not changes around the time a drug is started.
- It may be the weight loss doing the work, which is still helping but is not a psychiatric mechanism.

A Swedish cohort followed people with depression and anxiety who took GLP-1 drugs, and found something more interesting than a simple answer. Semaglutide was associated with a **42% lower** risk of worsening mental illness. Liraglutide was associated with an 18% lower risk, and exenatide and dulaglutide with none at all.[1]

## What was found

*Adjusted hazard ratios for worsening mental illness against non-use, in people with depression and anxiety.*

| Drug | Worsening mental illness |
| --- | --- |
| Semaglutide | 0.58 (95% CI 0.51–0.65) |
| Liraglutide | 0.82 (95% CI 0.76–0.89) |
| Exenatide | 1.01 (95% CI 0.69–1.46) |
| Dulaglutide | 1.01 (95% CI 0.85–1.20) |

For semaglutide the effect appeared across all three specific outcomes: worsening depression at 0.56, worsening anxiety at 0.62, and worsening substance use disorder at 0.53. Liraglutide moved only depression, at 0.74. Across the class as a whole, self-harm was lower, at 0.56 (confidence interval 0.34 to 0.92).[1]

## Why the split between drugs is the finding

We have now seen this shape twice. In a meta-analysis of atrial fibrillation, the class was neutral and the signal appeared specific to semaglutide, which we covered in [reading a 42% headline](https://glpwatchdog.org/research/glp1-and-atrial-fibrillation). Here again, two drugs move and two do not. The wider record on suicidal thoughts and psychiatric safety is gathered in [ten studies on GLP-1s and mental health](https://glpwatchdog.org/research/lists/top-glp1-mental-health-studies).

> An effect that lands on some members of a drug class and not others is either real pharmacology or a description of who receives which drug.

Both explanations are live. The design removes one large source of bias: it compares each person’s periods on a drug with their own periods off it, so stable differences between people cancel out.[1] It cannot remove everything. Each drug’s estimate comes only from the people who took it, and semaglutide, the newest and most effective of the four, reached different people than exenatide. Who reaches any of them is skewed as well: in diabetes, people with a mental health diagnosis have [a quarter of the odds of being prescribed a GLP-1](https://glpwatchdog.org/research/a-quarter-as-likely-to-be-offered-it). Whatever changes around the time someone starts a drug, such as closer contact with their care, can also move a mental-health trajectory.

There is also a straightforward mediating route that has nothing to do with the brain: semaglutide produces far more weight loss than exenatide, and losing a great deal of weight changes mobility, sleep, pain and how people are treated by others. A drug that improves depression *through* those channels is still helping, but that is not evidence of a direct psychiatric mechanism.

## The self-harm result, and where it sits

The class-wide self-harm finding matters because it speaks to the harm this drug class has been most publicly accused of. A hazard ratio of 0.56 points in the opposite direction from harm, in a population selected for existing depression and anxiety, the group in which any risk would show up first.

Set that against the spontaneous-reporting signal we covered in [the FAERS analysis](https://glpwatchdog.org/research/compounded-glp1-adverse-event-reports), which pointed the other way. These are not equally strong designs: a national cohort that compares each person with themselves beats voluntary reports with no denominator, and the regulatory picture is covered in [what happened with the suicidality signal](https://glpwatchdog.org/research/glp1-suicidal-ideation-what-happened).

> **None of this makes a GLP-1 a psychiatric treatment**, or a replacement for one; how these drugs sit alongside an existing antidepressant is covered in [our antidepressant interaction guide](https://glpwatchdog.org/research/antidepressants-and-a-glp1). The authors’ own conclusion is that for anxiety and depression co-occurring with diabetes and obesity these drugs *might* be dually effective options, and that randomized trials are warranted. A randomized trial of semaglutide for cognitive dysfunction in depression has since missed its primary endpoint, which we covered [separately](https://glpwatchdog.org/research/semaglutide-depression-cognition-trial).

## Frequently asked questions

### Do GLP-1 drugs worsen depression or anxiety?

This cohort found the opposite. Among people with depression and anxiety, semaglutide was associated with a 42% lower risk of worsening mental illness and liraglutide 18% lower, while exenatide and dulaglutide showed no association either way.

### Why did only some drugs in the class show an effect?

It is either a real pharmacological difference or a description of who gets which drug. The study compared each person with themselves, which cancels out stable differences between people. But each drug’s result comes from the people who took it, semaglutide reaches different patients than exenatide, and changes around the time a drug is started can also affect mental health.

### Could it just be the weight loss?

Plausibly. Semaglutide produces far more weight loss than exenatide, and losing a great deal of weight changes mobility, sleep, pain and how people are treated. A drug helping depression through those channels is still helping, but that is not evidence of a direct psychiatric effect.

### What about self-harm?

Across the class, self-harm was lower, with a hazard ratio of 0.56. That is notable because the population was selected for existing depression and anxiety, the group in which any risk would surface first.

### Should someone take one for depression?

No, and the authors do not suggest it. Their conclusion is that these might be dually effective options where depression or anxiety co-occurs with diabetes and obesity, and that randomized trials are needed. A randomized trial in depression has since missed its primary endpoint.

## References

1. Taipale H, Taylor M, Lähteenvuo M, et al. Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a nationwide cohort study. The Lancet Psychiatry. 2026. PMID: 41862258. https://pubmed.ncbi.nlm.nih.gov/41862258/

---

Cite as: GLP Watchdog, Nora Bissett, "GLP-1s and Worsening Mental Illness", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/glp1s-and-worsening-mental-illness

Canonical HTML page: https://glpwatchdog.org/research/glp1s-and-worsening-mental-illness

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
